Medium-chain acyl-coenzyme A (CoA) dehydrogenase (MCADH; EC 13.993) formation from 12,3-3Hjoctanoyl-CoA was 15% ofcontrol. When 3H20 formation was assayed with 200 MM 12,3VHjacyl-CoAs, 15 mM PMS, and 20 MM FAD in fibroblast sonic supernatants from seven MCD cell lines, SCADH, MCADH, and IVDH activities were 72-112% (P> 0.1), 4-9% (P < 0.01), and 86-135% (P > 0.1) of control, respectively, revealing no significant biochemical heterogeneity among these patients.
Introduction
Medium-chain acyl-coenzyme A (CoA)l dehydrogenase (MCADH) deficiency (MCD), first described clinically in 1976, is an inborn error of fatty acid metabolism due to a deficiency of the acylReceivedfor publication 18 June 1984 and in revisedform 22 May 1985.
1. Abbreviations used in this paper: ADH, acyl-CoA dehydrogenase; CoA, coenzyme A; CS, cell sonic supernatants; ETF, electron-transfer(ring) flavoprotein; FAD, flavin adenine dinucleotide; IVDH, isovaleryl-CoA dehydrogenase; MCADH, medium-chain acyl-CoA dehydrogenase; MCD, medium-chain acyl-CoA dehydrogenase deficiency; MS, fibroblast mitochondrial sonic supernatants; PMS, phenazine methosulfate; SCADH, short-chain acyl-CoA dehydrogenase.
CoA dehydrogenase (ADH) catalyzing the first step in the 13-oxidation ofmedium-chain-length fatty acids (1) (2) (3) (4) (5) . This disorder generally presents with nonketotic hypoglycemia, acidosis, and elevated urinary excretion ofstraight-chain C6-C1-w-dicarboxylic acids, although some patients in remission excrete few or no abnormal metabolites (1, (4) (5) (6) . These dicarboxylic acids are formed via co-oxidation ofaccumulated C10-CI2-monocarboxylic acids, which are then shortened by 13-oxidation to medium-chain lengths (7, 8) . Although a dicarboxylic aciduria has been noted in patients with glycogen storage disease, congenital lactic acidosis, severe ketoacidosis, multiple acyl-CoA dehydrogenation deficiency (glutaric aciduria type II), and systemic carnitine deficiency (9-13), the isolated excretion of straight-chain C6-C10-dicarboxylic acids without associated ketosis in MCD is consistent with the defective mitochondrial 13-oxidation produced by MCADH deficiency.
We first demonstrated deficient MCADH activity in MCD fibroblast mitochondrial sonic supernatants (MS) with an electron-transfer(ring) flavoprotein (ETF)-linked dye-reduction assay (2) . We describe here a tritium-release ADH assay employing [2,3-3H] acyl-CoAs as substrates. In MS and cell sonic supernatants (CS) from two MCD cell lines, this assay demonstrates that MCADH deficiency is secondary to defective acyl-CoA binding and/or dehydrogenation. We also show MCADH deficiency in CS from the patient first studied by Gregersen et al. (1) and Kolvraa et al. (3) and in CS or liver MS from five previously unstudied patients with the clinical phenotype and organic aciduria of MCD.
Methods [2,3-3H] Butyric acid (n-butanoic acid; 10 mCi/mmol), [2,3-3H] octanoic acid (5 mCi/mmol), and [2,3-3H~isovaleric acid (3-methyl-butanoic acid; 10 mCi/mmol) were obtained from New England Nuclear, Boston, MA. Phenazine methosulfate (5-methyl-phenazinium methyl sulfate; PMS) and flavin adenine dinucleotide (riboflavin 5'-adenosine diphosphate; FAD) were obtained from Sigma Chemical Co., St. Louis, MO. [2,3- 3H]Acyl-CoA esters were synthesized in our laboratory by a method previously described (14) .
For the MS and CS assays summarized in Tables I, II, and IV and  Figs. 1-4, skin fibroblasts were used from two unrelated MCD patients we studied earlier (S.G. and G.W.; 2, 5, 15, 16), six normal male infants, and two normal adults. For the CS assays summarized in Table V [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] were harvested by trypsinization, and mitochondria were isolated by a method described earlier (17) , except that digitonin treatment of the mitochondria was omitted. Mitochondria were sonicated in 0.4-0.6 ml of 20 mM KPi, pH 7.6, using a sonic disruptor (model 300 with a microtip; Fisher Scientific Co., Allied Corp., Pittsburgh, PA) at 0C for 30 s; the sonicates were then centrifuged at 100,000 g for I h. The MS were then assayed as described below. CS were obtained from two 150-cm2 culture flasks for each cell line (passage numbers 7-13); the cells were sonicated in 0.4-0.6 ml of 10 mM KPi, pH 7.6, containing 20 AM FAD, using the sonic disruptor (Fisher Scientific Co.) at 0C for I min, and centrifuged 100,000 g for I h. The CS obtained were assayed immediately.
The ETF-linked dye-reduction MCADH assay was done in fibroblast MS as described earlier with 0.2 mM N-ethylmaleimide, 50MM octanoylCoA, and 440 pmol of pure pig liver ETF provided by Dr. Carole L. Hall, Georgia Institute of Technology (2) . The tritium-release assay was performed in duplicate as described earlier (14, 17) , with these modifications: the reaction mixture contained 0.1 ml ofsonic supernatant (MS: 0. 1-0.3 mg protein; CS: 1.0-2.5 mg protein), 10 (14) . Liver MS was assayed with the tritium-release assay used for fibroblast MS, once immediately after isolation and again after storage for 2 wk at -70'C; ADH activities in B.V. and control MS were identical in both experiments (data not shown; P > 0.2).
In CS experiments, each tritium-release assay was performed in quadruplicate: one set of duplicates was counted directly, while the second set was lyophilized as we described previously (14, 18) . Although most of the radioactivity passing through the anion exchange column is contained in 3H20 and is lyophilizable (>95% in control MS; 67-86% in control CS), some nonlyophilizable 3H compounds, such as 3H-acyl carnitines, are produced during the assay and remain after lyophilization of the eluate (14, 18, 19) . The nonlyophilizable radioactivity, termed artifactual activity, is subtracted from total radioactive counts, yielding accurate quantitation of 3H20 released by enzymatic detritiation of the substrate. In the experiments summarized in Tables I, II, 
Results
In studies of ADH activities in isovaleric acidemia, Rhead and Tanaka (17) developed assays for short-chain acyl-CoA dehydrogenase (SCADH) and isovaleryl-CoA dehydrogenase (IVDH) that used [2,3-3H]butyryl-and -isovaleryl-CoAs as substrates (14) . (Fig. 3) . The deviation from linearity observed with [2,3-3H] isovaleryl-CoA obliged us to use a fairly constant amount of CS protein (1.5-2.5 mg/assay) when employing this substrate.
In CS, the rate of tritium release from [2,3-3Hlbutyryl-and -octanoyl-CoAs declined after 10 min (Fig. 4) . Thus, for convenience, CS assays with all three substrates were terminated at 10 min. In control fibroblast and liver MS incubated with [2,3- 3H]octanoyl-CoA, 96±5 and 98±2% of the total radioactivity passing through the column were lyophilizable, respectively, and represented 3H20 formation. In control CS incubated with this substrate, 86% of the total radioactivity was contained in 3H20 (Tables I, III , and IV).
Without PMS or FAD, [2,3-3H] octanoyl-CoA detritiation in MCD MS was 54% of control (P < 0.05; Table I ); in both control and MCD MS, similar proportions of the eluate radioactivity were contained in 3H20. Since PMS, an artificial electron acceptor, greatly stimulated tritium release by fibroblast and rat liver MS and by the purified pig and rat liver enzymes under similar assay conditions (14, 17) , we used this compound in our assay. Adding 10 mM PMS raised control MS ADH activities 16-fold, while MCD MCADH activity fell to 5% of control (P < 0.01), and SCADH activity was 73% of control (P > 0.1; Table I ). MCADH activity in MCD MS remained 5.5% (P of PMS. Similarly, FAD addition did not raise control or MCD MCADH activities in the ETF-linked dye-reduction assay (P > 0.8; Table II ). Lyophilization studies revealed that rates of 3H20 formation in MCD MS were only 3% of control (see footnote to Table I ). SCADH and IVDH activities in MCD MS were 86 and 96% of control, respectively (P > 0.1), with added FAD and PMS (Table I) . In separate experiments, equal amounts of MCD and control fibroblast MS were mixed, revealing 51% of control specific activity and confirming that no MCADH inhibitor is present in MCD MS (4; n = 2, data not shown).
In liver MS from patient B.V., SCADH and MCADH activities were 99 and 15% of control, respectively (Table III) . Control MCADH to SCADH activity ratios were 6.7-fold higher Table IV) . While these data demonstrate defective MCADH activity in MCD CS, the proportion of residual apparent MCADH activity in MCD CS is higher than predicted from the MS assays. Using a lyophilization procedure to quantitate precisely the 3H20 formed (14, 17) , MCADH activity in MCD CS was determined to be only 8% of control (P < 0.01), while SCADH and IVDH activities were 1 12 and 86% of control, respectively (P > 0.1; Table IV) , demonstrating MCADH deficiency in crude MCD fibroblast preparations. We then assayed ADH activities in CS from five other patients with the clinical presentation and organic aciduria of MCD, in four of whom ADH activities had not been assayed previously (Table V) . SCADH, MCADH, and IVDH activities were 73-85% (P > 0.1), 4-9% (P < 0.01), and 105-135% (P > 0.1) of control, respectively, in these cell lines, similar to the first two MCD patients we studied here (Table IV ; P > 0. 1).
Discussion
Since the tentative identification of the first case in 1976, MCD has become recognized as a clinically and biochemically distinct inborn error of fatty acid metabolism (1, (4) (5) (6) . While some patients are asymptomatic, the clinical phenotype is commonly characterized by episodic hypoglycemia, often provoked by fasting, unaccompanied by ketosis, and frequently associated with urinary excretion of straight-chain C6-C10-co-dicarboxylic acids. These compounds are also excreted in other disorders, such as systemic carnitine deficiency and the multiple acyl-CoA dehy- (14) . Unlike the dye-reduction assay, the tritium-release assay is free from interferences by both nonspecific endogenous reductants and CoASH derived from thioesterase-catalyzed acyl-CoA hydrolysis (2, 20) . This method can accurately measure ADH activities in crude tissue homogenates, intact and sonicated mitochondria, and purified enzymes, and has been extensively characterized in the rat liver and human Normal controls (n) 1,850±434 (6) 1,790±379 (6) MCD patients (n) 134±34 (7) 106±20 (7) 0.2-0.4 mg of fibroblast MS protein was preincubated at 370C for 1 min with and without 20 AM FAD. MCADH activity was then assayed as described (2) I,010±216t (2) 471±129"1 (2) 100 MM [2,3-3H] butyryl-(10 mCi/mmol) and -octanoyl-CoAs (5 mCi/ mmol) were incubated with 0.2-0.5 mg liver MS protein, 20 MM FAD and 10 mM PMS for 15 min at 370C. The 3H20 formed was separated from unreacted substrate by passage of the reaction mixture over an AG-I anion exchange column; duplicate samples of the column eluates were then lyophilized at pH 6. The proportion of lyophilizable radioactivity represents 3H20 formed by detritiation of the substrates. Proportion of lyophilizable radioactivity: * 96±4% (n = 6); t 100% (n = 1); § 98±2% (n = 6); 11 96% (n = 1). and 15 mM PMS at 370C for 10 min. After passage of the reaction mixture over AG-I anion exchange resin, duplicate samples were lyophilized at pH 6 and the nonlyophilizable radioactivity remaining was taken as artifactual activity. Lyophilizable radioactivity represents 3H20 formed by detritiation of the substrates.
electron transfer from MCADH to electron acceptors probably does not contribute to deficient MCADH activity in MCD. These observations effectively localize the catalytic defect in MCD to deficient substrate binding and/or dehydrogenation by MCADH. This conclusion is strengthened by our assays being performed in a mitochondrial matrix subfraction, rather than cell or tissue homogenates. In addition, the tritium-release method possesses the catalytic specificity to support this conclusion, while assays using ETF as an electron acceptor do not (2, 4). Other investigators have not systematically studied the effects of FAD addition on MCD MCADH activity in vitro, although Gregersen et al. (3) found no decrease in MCD MCADH activity when they lowered FAD concentration from 250 to 1 AM. Addition of 20 AM FAD, the ionically bound cofactor for all known ADH (21, 23, 24) , increased MCADH activity little in control or MCD MS; MCD MCADH activity remained low at 5-6% of control using both the tritium-release and dye-reduction assays. These observations suggest that defective FAD binding to an altered MCADH apoenzyme does not explain MCADH deficiency in MCD. Since the Michaelis constants (Km's) ofthe ADH for FAD are quite low, ranging from 0.43 to 2.4 AM (21) (22) (23) , these data do not exclude the existence of a mutant MCADH apoenzyme in MCD with a K. for FAD 100-fold greater than normal and/or the accelerated degradation of such a protein in vivo (27) .
Combining enzyme preparations from two MCD cell lines did not change MCD MCADH activities in either MS or CS (Figs. 1-4) , which suggests that no intragenic complementation The assay conditions are identical to those described in MiM FAD raised control SCADH activities 31% and revealed MCD SCADH activity to be 86% of control (P > 0.1). Using the dye-reduction assay, we found SCADH activity in MCD MS to be somewhat lower at 55% (P < 0.05) of control (2) . These moderate reductions in MCD SCADH activity may reflect the consequences of absent MCADH activity on the dehydrogenation of butyryl-CoA. Mammalian MCADHs, isolated from pig and rat liver, possess varying activities toward butyryl-CoA (21, 24, 29) , although the chain-length specificity of human fibroblast MCADH is not known. IVDH activities were similar in both control and MCD MS. We anticipated this result, since isovaleryl-CoA is dehydrogenated by a specific and distinct IVDH. Pure rat liver IVDH has no activity toward hexanoyl-or octanoyl-CoA; conversely, rat liver MCADH cannot dehydrogenate any branched-chain acyl-CoA (21, 22) .
We then modified the method for ADH assay in whole fibroblast preparations (CS), since an effective assay for ADH activity in CS would speed diagnosis of MCD and related disorders. In our first three experiments, apparent MCADH activity in MCD CS proved to be 23% of control. While these observations were generally consistent with the results of both the dye-reduction and tritium-release MS assays, apparent residual MCADH activity in MCD CS was more elevated than we predicted. However, some of our earlier observations can explain this discrepancy. In (1, (3) (4) (5) (6) 30) . Subtracting these artifactual activities from the apparent CS activities yields ADH activities due only to 3H20 formation and clearly demonstrates MCADH deficiency in MCD CS (8% of control). Subsequently, in fibroblasts or liver from six other patients with the characteristic clinical phenotype and organic aciduria, we successfully confirmed MCADH deficiency and the diagnosis of MCD. Including our present data, we have studied 9 of the 14 published MCD patients in whom MCADH deficiency has been confirmed in vitro (2-5, 31, 32) . We have found no evidence for significant biochemical heterogeneity in MCD, since SCADH, MCADH, IVDH, and long-chain ADH activities are similar in all cell lines we studied with the tritium-release and/or dye-reduction methods (2; other data not shown). Thus, clinical heterogeneity in MCD probably reflects individual differences in diet, gluconeogenesis, glucose homeostasis, and/or efficiency of acyl-CoA detoxification (1, (4) (5) (6) (7) (8) .
Other investigators have also developed assays for ADH activities in MCD cell homogenates. Stanley et al. (4) used a complex assay that quantitated ADH activity by following ETF reduction fluorometrically, but which did not permit calculation of specific activities. With octanoyl-CoA as substrate, liver homogenates from their three patients had <2.5% of control MCADH activity; liver SCADH and IVDH activities appeared identical to control, using butyryl-CoA and isovaleryl-CoA as substrates, respectively. Kolvraa et al. (3) and Divry et al. (5) quantitated decanoyl-CoA conversion to 2-decenoyl-CoA and found 28 and 20% of control MCADH activity in fibroblast homogenates from MCD patients R.B. and S.G., respectively (3, 5) , results substantially higher than the 8-9% residual MCADH activities we found in the same cell lines (Tables IV  and V) . These high residual activities suggest that peroxisomal acyl-CoA oxidase is active in their preparations (33, 34) . This flavoenzyme catalyzes the formation of 2-enoyl-CoA and H202 from acyl-CoAs and is most active with C12-C18-acyl-CoAs, although C6-C8-acyl-CoAs are also oxidized (33) . Both the tritiumrelease and 2-enoyl-CoA methods (3) will detect acyl-CoA oxidation catalyzed by the peroxisomal enzyme, while assays using ETF as an electron acceptor will not (2, 4) . Peroxisomal acylCoA oxidase activity might also explain the high apparent Km offibroblast MCADH toward octanoyl-CoA that Gregersen and Kolvraa (35) found in one MCD cell line; they concluded that decreased amounts of MCADH apoenzyme are made in MCD. However Ikeda and co-workers (36) found no cross-reactingmaterial-negative or molecular weight MCADH variants in 10 other MCD cell lines. Demonstration of genetic heterogeneity in MCD must await enzymatic, immunochemical, complementation, and restriction enzyme studies in other MCD cell lines.
